Zenas Biopharma Inc

Research Zenas Biopharma Inc (ZBIO) on Bullrun: market cap USD 1.61B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerZBIO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.61B
• Financial periodFY2025
• RevenueUSD 10.00M
• Revenue growth100.0%
• Net income-USD 377.74M
• Free cash flow-USD 172.35M

Valuation Snapshot

latest market cap is USD 1.61B.

About Zenas Biopharma Inc

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody;

Frequently asked questions

What is Zenas Biopharma Inc's market cap?

Zenas Biopharma Inc's market capitalization is USD 1.61B.

What does Zenas Biopharma Inc do?

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.